Noninvasive imaging plays a growing role in the drug development process, especially in cardiovascular. The growth in use of molecular imaging has been increasingly applied to improve and accelerate aspects of preclinical steps in drug development. These include the evaluation of on-target and off-target effects of candidate therapies,, the identification of appropriate therapeutic targets, the assessment of dose response and the evaluation of drug or biological pharmacodynamics amongst others. Molecular imaging has been successfully used in early clinical studies, to demonstrate proof-of-concept or to explain treatment effect. But how can biologics manufacturers capitalize on this area in the current climate?

In response, we want to share a presentation deck titled “Use of Imaging to Assess Drug Delivery via Targeted Biologics” from Andy Boswell at Genentech (a member of the Roche Group). Dr. Boswell delivered this talk at one of our recent Global Drug Bioavailability Enhancement Summits. This presentation discusses the wide range of uses for radiometric methods in quantitative pharmacology, discussing the use of radiometric assays which offer distinct advantages for measuring biologic drug distribution in tissues, reagents for tumor antigen imaging and more. It also discusses various examples and imaging case studies, as well as aspects of the importance of chemistry in molecular imaging.

Scroll through the presentation below……